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INTRODUCTION: 
Oral delivery is currently the gold standard in the 
pharmaceutical industry where it is regarded as the 
safest, most convenient and an economical method of 
drug delivery having the highest patient compliance.
1
 
The fast dissolving drug delivery systems came into 
existence in the early 1970’s. Fast dissolving drug 
delivery systems have a major advantage over 
conventional dosage forms since the drug rapidly 
disintegrates and dissolves without the use of water1. 
Many patients have difficulty in swallowing tablets 
and capsules specially in cases of dysphagia, coughing, 
sudden allergic attacks or unavailability of water. 
Thus, to eliminate the drawbacks of tablets, fast 
dissolving films can be developed 
2, 3
. According to the 
film forming material characteristics, the manufacture 
of the dosage forms can present different critical 
issues. Common problems are caused by foaming 
during the film formation due to the heating of the 
material or solvent evaporation, the flaking during the 
slitting and the cracking in the cutting phase. 
Furthermore, the films should be stable to moisture 
overtime. Finally, to facilitate the handling they have 
to be flexible and exhibit a suitable tensile strength and 
do not stick to the packaging materials and fingers.  
Formulation of these systems is usually 
straightforward; the polymer and drug are dissolved in 
a solvent and a film is cast by solvent evaporation.
4, 5
 
Despite of tremendous advancement in drug delivery 
the oral route of drug administration is the most 
important method of administration of drug for 
systemic effect. Oral route is most preferred route by 
medical practitioners and manufacturer due to highest 
acceptability of patients. About 60% of all dosage 
forms available are the oral solid dosage form. About 
60% of all dosage forms available are the oral solid 
dosage form. The lower bioavailability, long onset 
time and dysphagia patients turned the manufacturer to 
the parenterals and liquid orals. But the liquid orals 
(syrup, suspension, emulsion etc) have the problem of 
accurate dosing mainly and parenterals are painful 
drug delivery, so most patient incompliance.  
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ABSTRACT: 
Montelukast sodium is a leukotriene receptor antagonist (LTRA) used in maintenance treatment of asthma and to relieve 
symptoms of seasonal allergies. Fast dissolving drug delivery system offers a way out for those patients having difficulty in 
swallowing tablets/capsules etc. The present exploration was undertaken with the intention of formulating of the montelukast 
sodium fast dissolving oral thin films allowing fast reproducible drug dissolution in oral cavity thus bypassing first pass 
metabolism, to augment the expediency and acquiescence by the elderly and pediatric patients. Montelukast fast dissolving oral 
thin films were equipped by solvent casting method with using diverse film-forming agents like HPMC, PVP, PEG 400, 
glycerol as a plasticizer and mannitol as filler and sweetener. Oral thin films were characterized for weight variation, thickness, 
surface pH, folding endurance, drug content, disintegration time, drug polymer compatibility (IR Study and in-vitro dissolution 
studies. Montelukast oral thin films based on evaluation studies HPMC showed optimum performance against other 
formulations. The prepared films were clear, transparent, and had a smooth surface. The surface pH was found to be in the 
range of 6.31 to 6.75 which is close to salivary pH, which indicates that films may have less potential to irritate the oral 
mucosa, thereby they are comfortable. The drug content of all the films was in the range of 96.80 to 99.12 suggesting that drug 
was uniformly dispersed throughout all films. The In-vitro disintegration time of films prepared with HPMC was in the range of 
25.38 to 39.12 sec. As the concentration of SSG increases the in-vitro disintegration time of the films decreases. It was 
accomplished that the fast dissolving oral thin films of montelukast can be prepared by solvent casting technique with improved 
dissolution rate, better patient compliance and effective therapy.  
Keywords: Montelukast sodium, solvent casting, Folding endurance, in-vitro dissolution and oral thin films.  
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The montelukast sodium is a leukotriene receptor 
antagonist (LTRA) used for the maintenance treatment 
of asthma, chronic asthma attacks and to relive 
symptoms of seasonal allergies. The main drawback of 
conventional montelukast sodium formulation is that it 
undergoes hepatic first pass metabolism. Thus, it shows 
plasma or biological half-life 2.5 to 5.5 h, thereby 
decreasing bioavailability upto 64%. Montelukast 
Sodium is given in a dose of 10mg once daily. The 
present study is aim to formulate and characterized fast 
dissolving oral films of Montelukast Sodium for rapid 
dissolution of drug and absorption which may produce 
the rapid onset of action in the management of asthma 
and also to improve the bioavailability of the drug. It 
has extensive first-pass metabolism and show a very 
poor dissolution rates in order to overcome this problem 
preparation of oral thin films. The main objectives of 
the present study were to prepare and evaluate the oral 
thin films of montelukast sodium and to study the 
various formulation variables that affect in vitro 
performance.  
MATERIALS AND METHODS: 
Materials: 
Montelukast sodium was obtained as a gift sample from 
Unimark remedies Ltd, Mumbai, India. HPMC E50 was 
procured from Yarrow chem. Products, Mumbai, India. 
PEG 400, PVP, PVA was obtained from S.D.Fine 
private limited, Mumbai, India. All the ingredients were 
of analytical grade. 
Method: 
Fabrication of montelukast sodium oral thin films:  
The oral thin films of montelukast sodium were 
fabricated in laboratory using HPMC by solvent casting 
method. Hydroxy propyl methyl cellulose (HPMC) is 
known for its good film forming properties and has 
excellent acceptability. For the fabrication of films, 
propylene glycol was used as a plasticizer, glycerin as 
humectant and mannitol was used as a sweetener. The 
required quantity of montelukast sodium was dissolved 
in 10 ml of distilled water containing various grades of 
HPMC to form polymeric dispersion. Briefly, propylene 
glycol, glycerin, aspartame and various polyhydric 
alcohols were dissolved in 5 ml of 50% v/v ethanol. 
Alcoholic solution and the polymeric dispersion were 
mixed to obtain a homogeneous dispersion and 20 ml of 
the dispersion was cast onto each polypropylene petri 
plate. The composition of various films is revealed in 
Table 1. The dispersion was dried at 40–45 °C. The 
films were carefully removed from petri plates and 
stored in an air tight glass bottle. The films were 
characterized for imperfections and cuts, peel ability 
without rupturing, folding and cracking endurance and 
surface roughness.
10 
 
Table 1 Different composition of oral thin films of montelukast sodium  
S.No Montelukast 
sodium (mg) 
HPMC E 
50 (mg) 
PVA(2%) 
ml 
PVP 
(mg) 
Glycerol 
(ml) 
Ethanol 
(ml) 
Water 
(ml) upto 
PEG-400 
(ml) 
MOF1 20 100 5% --- 0.04 2 10 0.05 
MOF2 20 100 --- --- 0.04 2 10 0.05 
MOF3 20 100 5% 20 0.04 2 10 0.05 
MOF4 20 100 --- --- 0.04 2 10 0.05 
MOF5 20 100 5% 20 0.04 2 10 0.05 
MOF6 20 100 --- --- 0.04 2 10 0.05 
 
Characterization of oral films of montelukast 
sodium: 
Spectrum measurement: 
The standard stock solution of Montelukast sodium 
having concentration of 16 μg/ml in buffer 
0.5% SLS was scanned between 200-400nm in UV-
Visible Spectrometer. The maximum 
absorption (λmax) of Montelukast sodium peak was 
obtained at 345nm. 
FT-IR Studies  
Compatibility of drug and polymers was premeditated 
using Fourier Transform Infrared (FTIR) spectroscopy. 
FTIR Spectrum was recorded between 600-4000 cm-1 
using Shimadzu 160a, Kyoto, Japan by KBr Disc 
method.  
Surface pH:  
Film is slightly wet with the help of water. The pH is 
measured by bringing the electrode in contact with the 
surface of the oral film. This study is performed on 
three films of each formulation and means ± S.D 
calculated. 
11 
Weight uniformity: 
The cast film was cut at different places and the weight 
of each film was checked with the help 
of an electronic balance and the average weight was 
calculated.
12 
Film thickness: The thickness of each film was 
measured using micrometer screw gauge at different 
positions of the film and the average was calculated. 
13
 
Folding endurance: 
Folding endurance was determined by repeatedly 
folding the film at the same position until it 
breaks. The number of times the films can be folded 
without breaking is termed as the folding 
endurance value. 
14, 15 
Drug content: 
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Drug content of all batches of MTS thin films was 
determined by UV- spectrophotometric method. For this 
one strip of 5 cm
2 
was dissolved in 100ml of pH 6.8 
buffer. Then the solution was suitably diluted and the 
absorbance was recorded at 240nm.  
In vitro disintegration time: 
A glass Petri dish (6.8 cm diameter) was filled with 10 
ml of water and the film was carefully placed in the 
center. The set up was left undisturbed. The time for the 
film to completely disintegrate into fine particles was 
noted. The test was performed four times on each 
formulation and mean value was reported. Wherever 
applicable, the mean disintegration times were 
subjected to statistical analysis by non-paired student t 
test. Differences in means were considered statistically 
significant at P<0.05.
16 
In-vitro dissolution studies:  
In-vitro dissolution of fast dissolving film was studied 
in USP paddle dissolution test apparatus using 
phosphate buffer pH 6.8 as the dissolution medium. The 
temperature was maintained at 37±0.5ºC throughout the 
experiment. 5ml Sample was withdrawn at 50sec 
intervals and the same quantity was replaced with 
phosphate buffer of pH 6.8. The cumulative percentage 
of drug released was determined using UV visible 
spectrophotometer at 342 nm. 
17
 
Kinetic modeling of oral thin films:  
The dissolution profile of montelukast sodium oral thin 
films followed first order to ascertain the kinetic 
modeling of the drug release: 
Zero order  
In many of the modified release dosage forms, 
particularly sustained or controlled release dosage 
forms (those dosage forms that release the drug in 
planned, predictable and slower than the normal 
manner), is zero-order kinetic.  
m = k * t 
Where, k is zero-order constant, m is the % drug 
unreleased and t is the time. The plot of % drug 
unreleased (released) versus time is the linear.  
First order  
Most conventional dosage forms exhibits this 
dissolution mechanism. Some modified release 
preparation, particularly prolonged release 
formulations, adheres to this type of dissolution pattern.  
m = ea * e-bt 
Where, a is the intercept and b is the slop. It assumes 
that the drug molecules, diffuses out through a gel like 
layer formed around the drug during the dissolution 
process. A plot of log % drug release versus time is the 
linear.  
Stability studies:  
The purpose of the stability testing is to provide 
evidence on how the quality of a drug substance or drug 
product varies with time under the influence of a variety 
of environmental factors such as temperature, humidity 
and light, enabling recommended storage condition, re-
test periods and shelf life. The stability studies were 
carried out as per International Conference of 
harmonization (ICH) Guidelines. Stability studies were 
carried out at 40º C / 75% RH for 3 months. The 
optimized film formulations were packed in amber-
colored bottles, which were tightly plugged with cotton 
and capped. They were then stored at 40ºC / 75% RH 
for 3months and evaluated for their physical 
appearance, drug content and in-vitro dispersion time at 
specified intervals of time. 
18
 
RESULTS AND DISCUSSION:  
Physical appearance and surface texture of film: 
All the films appeared uniform. All the films were 
found to be transparent and the surfaces of the films 
were smooth in nature. Thus it was concluded that the 
films were elegant and aesthetically appealing. 
FT-IR Studies: 
The possible interaction between drug and excipients 
used in the formulation development of montelukast 
sodium was studied by FTIR spectroscopy. The FTIR 
spectrum of montelukast depicts a characteristic 
absorption band at 3437 cm-1 representing the presence 
of OH group. The CH2 , C-N vibrations showed a 
characteristic absorption band in the region of 2926 cm-
1 and 1265 cm-1. The spectrum of montelukast-
polymer physical mixtures showed absorption bands at 
3414 cm-1, 2926 cm-1 and 1266 cm-1 OH, The CH2 
and C-N. It indicates drug and drug containing physical 
mixture absorption bands were near that there was no 
chemical and physical change in the functional groups 
present in montelukast sodium.  
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Figure 1: FT-IR spectra of montelukast sodium 
Surface pH:  
The surface pH was found to be in the range of 6.31 to 
6.75 which is close to salivary pH, which indicates that 
films may have less potential to irritate the oral mucosa, 
thereby they are comfortable. The results are given in 
Table 2.  
Weight uniformity: 
Weight variation was carried out and this varied within 
the range of 39.08 to 43.24 mg. As per USP 
requirements, the formulations were found to meet the 
criteria for weight variation.  
Film thickness:  
All the films have uniform thickness throughout. The 
thickness of all the formulations ranged between 0.214 
to 0.237 mm. In all the cases the standard deviation 
values are very low which suggest the prepared films 
were uniform in thickness. The results are given in 
Table 2.  
Folding endurance: 
Folding endurance measures the ability of patch to 
withstand rupture, higher the folding endurance lower 
will be chances of film to rupture easily. Folding 
endurance value was more than 200 which indicated 
good elasticity of the films. The presence of plasticizer 
was the reason for this good elasticity. The results are 
given in Table 3.  
Drug content: 
Drug content was evaluated and it varied within the 
range of 96.80±2.87 to 99.12±1.76. The drug content 
was found to be low for MOF6 i.e. 96.80 and more for 
MF1 i.e. 99.12 As per USP requirements, drug content 
was found to be within the limits i.e. 85-115%. 
 
Table 2: Characterization parameters of oral film of montelukast sodium 
Formulation MOF1 MOF2 MOF3 MOF4 MOF5 MOF6 
Weight variation (mg) 
±SD 
40.12±0.178 43.24±0.065 39.08±0.121 40.78±0.351 41.11±0.564 42.66±0.306 
Thickness (mm) ±SD 0.214±.0004 0.237±0.005 0.223±0.010 0.219±0.026 0.233±0.018 0.220±0.008 
Surface pH ± SD 6.69±0.122 6.45±0.272 6.49±0.002 6.31±0.008 6.35±0.167 6.75±0.135 
Folding endurance 
±SD 
266±4.12 272±1.34 262±3.23 248±2.08 265±1.11 255±0.09 
Disintegration time 
±SD 
28.23±1.17 25.58±2.00 37.98±1.56 34.65±2.31 39.12±3.41 38.98±4.11 
Drug content ±SD 99.12±1.76 98.89±1.22 97.54±0.09 98.65±2.23 99.44±1.31 96.80±2.87 
 
In vitro disintegration time: 
In vivo Disintegrating time is defined as the time 
(seconds) at which a film breaks when brought into the 
contact with water or saliva. All the formulations were 
found to disintegrate within 60 sec. Formulation MOF2 
showed less disintegration time i.e. 25.58 sec and 
formulation MOF5 showed more disintegration time i.e. 
39.12sec.  
 
In-vitro dissolution studies:  
In vitro drug release was carried out in USP basket type 
dissolution apparatus. MOF5 formulation released more 
amount of drug i.e. 99.44 and formulation MOF6 
released less amount of drug i.e. 96.80%. Dissolution 
rate increases with decrease in disintegration time. In 
vitro dissolution studies graphs are mentioned in figure 
2. More amount of drug release indicates rapid onset of 
action and hence faster relief. 
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Figure 2: In-vitro dissolution profiles of formulation MOF1 to MOF6 
 
Kinetic modeling of oral thin films:  
Table 3 and fig 3 showing R2 values for zero order release and first order release. The values for first order were closer 
to 1 than those for zero order. So, it was assumed that all the formulations followed first order kinetics. The release is 
found concentration dependent.  
Table 3: Kinetic modeling of montelukast sodium oral thin films 
Formulations  K
-1
(MIN
-1
)  T50  R  DP10  First order R
2
  Zero order R
2
  
MOF1 0.21 6.02 0.981  6592  0.910 0.812  
MOF2 0.12  7.11  0.986  61.92  0.994  0.805  
MOF3 0.03  13.8  0.988  70.11  0.947  0.614  
MOF4 0.17  12.3  0.981  73.11  0.988  0.517  
MOF5 0.04  10.1  0.971  78.97  0.991  0.588  
MOF6 0.11  15.0  0.976  72.31  0.958  0.520 
 
Stability studies:  
When the oral film preparation was stored either in the aluminum package or under unwrapped condition at 40 ◦C and 
75% in humidity for 4–8 weeks, no apparent changes in the shape, color or flexibility were observed.  
Table 4: Stability studies data for oral films of montelukast sodium 
Formulations MOF3 MOF5 
 I Month II Month III Month I Month II Month III Month 
Disintegration 
time 
20 24 22 25 27 24 
Surface pH 6.40 6.42 6.41 6.44 6.44 6.43 
Drug content 
(%) 
99.21 98.89 97.90 98.45 99.10 97.34 
 
CONCLUSION: 
Fast dissolving films fulfill all the aforementioned 
requirements of potential solid oral dosage form for 
local delivery of montelukast sodium. In present 
research work, an attempt has been made to prepare 
mouth dissolving films of montelukast Sodium by 
solvent casting method using film forming polymer 
HPMC, PVA. Montelukast Sodium is freely soluble in 
water but its bioavailability is about 64%. Based on the 
in-vitro disintegration time, formulation MOF1 and 
0
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MOF2 were found to be promising and showed a 
disintegration time of 25.58 and 28.23 sec respectively. 
However this FDF is useful for the improving of the 
bioavailability of the drug moreover, it revealed an 
excellent stability and dissolution profile. 
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